Followers | 72 |
Posts | 4230 |
Boards Moderated | 2 |
Alias Born | 08/21/2015 |
Thursday, April 29, 2021 11:55:17 AM
Now that the uplisting is over, what should we be looking forward to? Well in the near-term I would say that the following few things might be good to keep an eye out for:
Annual and Special Meeting on May 27th, 2021: Annoying who was a qualifying shareholder as of April 12, 2021 will be eligible to vote on the changes laid out as the purpose of this meeting. You can find all of those likely in your email, in your snail-mail boxes, or through the SEDAR filings.
Project Lucy Trial Results: Rumour has it that Project Lucy's most recent trial is wrapping up on May 1st, 2021. The results won't be out the day of, but that is something you should definitely be on the lookout for. Trials are everything with the company and position results in any capacity are ideal.
ATAI Nasdaq IPO: ATAI has announced their IPO onto the NASDAQ and that is expected to happen in the coming weeks (no one really knows when though). Touted as a big-dawg in the sector, it will for sure bring a lot of attention to the psychedelic space.
Some Other Important Points:
MindMed is not a get-rich-quick stock. They have no revenue and they likely will not for many years to come. That being said, there are still plenty of things to be excited about between now and approvals.
We love MindMed for its diverse pipeline and promising developments. That love comes with a cost... Trials are incredibly expensive to conduct. One of the best ways that MindMed can support these expenses is through more share offerings. This is something you should be prepared for and it's something they are ready to do (see the section on base self prospectus above).
Alright, that's all for today.
Stay Happy, Stay Healthy
Recent MNMD News
- MindMed to Participate in June Conferences • Business Wire • 05/28/2024 11:00:00 AM
- MindMed to Participate at May Investor Conferences • Business Wire • 05/09/2024 08:01:00 PM
- New Studies Presented at the International Society for Health Economics and Outcomes Research Meeting (ISPOR 24) Show Growing Burden and Impact of Generalized Anxiety Disorder (GAD) in the US • Business Wire • 05/09/2024 12:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/08/2024 08:15:41 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/08/2024 08:10:12 PM
- MindMed Reports First Quarter 2024 Financial Results and Business Updates • Business Wire • 05/08/2024 08:01:00 PM
- MindMed Presents Phase 2b Study of MM120 for Generalized Anxiety Disorder (GAD) at American Psychiatric Association (APA) Annual Meeting in New York • Business Wire • 05/04/2024 12:00:00 PM
- MindMed to Host Conference Call and Webcast to Discuss First Quarter 2024 Financial Results and Provide Business Update • Business Wire • 05/02/2024 11:00:00 AM
- MindMed to Present at Upcoming May Medical Conferences • Business Wire • 04/25/2024 11:00:00 AM
- MindMed to Present at Upcoming April Medical Conferences • Business Wire • 04/02/2024 11:00:00 AM
- MindMed Announces Voluntary Delisting from Cboe Canada • Business Wire • 04/01/2024 09:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/11/2024 12:32:03 PM
- MindMed to Participate in the Leerink Partners 2024 Global Biopharma Conference • Business Wire • 03/11/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/07/2024 01:19:43 PM
- Mind Medicine (MindMed) Inc. Announces Pricing of Underwritten Offering of Common Shares and Concurrent Private Placement • Business Wire • 03/07/2024 12:13:00 PM
- Form S-3MEF - Registration adding securities to prior Form S-3 registration [Rule 462(b)] • Edgar (US Regulatory) • 03/07/2024 12:09:01 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/07/2024 11:56:00 AM
- MindMed Receives FDA Breakthrough Therapy Designation and Announces Positive 12-Week Durability Data From Phase 2B Study of MM120 for Generalized Anxiety Disorder • Business Wire • 03/07/2024 11:00:00 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/01/2024 06:56:37 PM
- MindMed to Host Conference Call and Webcast to Discuss Data Update for MM120 • Business Wire • 03/01/2024 02:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/29/2024 09:45:50 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/29/2024 09:45:44 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/29/2024 09:45:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/29/2024 09:45:16 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/28/2024 12:20:33 PM
PickleJar Debuts Nationwide Contest With Brian Kelley for Fans to Win a Three-Day Bahama Cruise • NREG • Jun 3, 2024 8:45 AM
ILUS Provides an Update on the Binding Term Sheet Signed with Actelis Networks (NASDAQ: ASNS) • ILUS • May 31, 2024 12:52 PM
Element79 Gold To Provide Summary and Update on Active Exploration Program, Community Relations at RMEC on June 4 • ELEM • May 30, 2024 1:18 PM
Branded Legacy Secures Exclusive Extraction Partnership with One of the World's Largest Kava Distributors and Producers • BLEG • May 30, 2024 8:30 AM
ECGI Holdings, Inc. Announces $2 Million Debt-to-Equity Conversion • ECGI • May 30, 2024 8:30 AM
North Bay Resources Reports Assays up to >25% Mg, 0.1% Ni, 0.1% Cu, 0.01% Co, 0.3 ppm Pt at Tulameen Platinum Project, British Columbia • NBRI • May 29, 2024 9:03 AM